FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.
What happened
FDA inspected Natural Essentials' drug manufacturing facility in Streetsboro, Ohio, from June 22 to 26, 2026. FDA found significant current good manufacturing practice (CGMP) violations for finished OTC drugs, including inadequate investigations of failing test results, unsuitable microbial test methods, missing identity testing on incoming components, and incomplete laboratory records. FDA reviewed the company's August 11, 2026 response to the Form FDA 483 inspection observations and found it inadequate.
What FDA found
The firm did not thoroughly investigate out-of-specification (failing) and out-of-limit test results, including microbial failures, and released lots based on retesting without scientific justification.
21 CFR 211.192The firm's laboratory specifications and microbial test methods were not scientifically sound; an internal specification exceeded the United States Pharmacopeia (USP) monograph limit, and microbial methods were not shown equivalent to USP methods.
21 CFR 211.160(b)The firm failed to perform required identity testing on each incoming lot of a component used in OTC drugs, including a limit test for a hazardous impurity.
21 CFR 211.84(d)(1)The firm did not keep complete laboratory records; it retained raw chromatographic data but not processed chromatograms and used uncontrolled spreadsheets for CGMP data.
21 CFR 211.194(a)
What FDA wants
FDA tells Natural Essentials to respond in writing within 15 business days with corrective actions, including retrospective failing-result reviews, risk assessments, laboratory and data-integrity remediation, and component identity testing commitments. FDA also recommends engaging a qualified CGMP consultant to audit the operation and verify corrective actions.
Who should pay attention
- OTC drug brands and distributors that source products from this facility
- quality teams managing failing-test investigations and microbial methods
- manufacturers that test incoming drug components for identity and impurities
This is a summary. Read the original letter on fda.gov.